Poland· PL-100532782
Exdensur
A other systemic drugs for obstructive airway diseases product containing depemokimab, registered in Poland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Depemokimab is registered in 3 of 19 countries.
Countries holding a registration under ATC R03DX (other systemic drugs for obstructive airway diseases), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Depemokimab · ATC R03DX
3 / 19 countries
- Czechiaprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Depemokimab
- Manufacturer
- GlaxoSmithKline Trading Services Limited
- Country
- Poland (PL)
- ATC code
- R03DX
- ATC class
- Other systemic drugs for obstructive airway diseases
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05901549673050
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Depemokimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomExdensur 100mg/1ml solution for injection pre-filled pensGlaxoSmithKline UK Ltd
- CzechiaEXDENSURGlaxoSmithKline Trading Services Limited, Dublin
- SpainEXDENSUR 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- IcelandEXDENSURGlaxoSmithKline Trading Services Limited
- SwedenEXDENSUR 100 mg Injektionsvätska, lösning i förfylld injektionspennaGlaxoSmithKline Trading Services Ltd
- BelgiumExdensur 100 mgGlaxoSmithKline Trading Services
- United StatesExdensurGlaxoSmithKline LLC
- FinlandEXDENSURGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exdensur
- Liechtenstein · Exdensur
- Norway · Exdensur
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/76c40a73-5b73-4e7c-bc32-f3c8abe560a8 GET /v1/drugs/76c40a73-5b73-4e7c-bc32-f3c8abe560a8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
"source": "urpl",
"strength": "100 mg",
"packaging": "05901549673050 ¦ Rpz ¦ EU/1/25/2007/001 ¦ 165738\n1 strzyk. 1 ml",
"substance": "Depemokimab/100 mg",
"common_name": "Depemokimab",
"pl_product_id": "100532782",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about depemokimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.